SOPHiA GENETICS announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ at the Association for Molecular Pathology (AMP) Annual Meeting. This new application provides organizations worldwide with access to Memorial Sloan Kettering Cancer Center's (MSK) comprehensive genomic profiling (CGP) assay, enhancing precision oncology globally.
The MSK-IMPACT® solution is designed to process more precise oncology analysis by improving the accuracy of somatic mutation detection, including in genes relevant for pharmaceutical industry R&D pipelines like MTAP. It utilizes a matched tumor-normal analysis approach to minimize the risk of misclassifying germline variants as tumor-specific, offering high accuracy and efficiency.
SOFIVA GENOMICS in Taiwan is among the first to adopt this application, expanding its tumor profiling capabilities alongside the liquid biopsy test MSK-ACCESS®. The workflow from DNA extraction to final report takes approximately five days, and users benefit from access to OncoKB™, MSK's Precision Oncology Knowledge Base, for enhanced interpretive power.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.